Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – HIVDRP Website

HIV Drug Resistance Program

Selected News Items
Interviews and Press Releases
Frederick News-Post Article on Student Intern Bilguujin Dorjsuren

The following front-page article features Bilguujin Dorjsuren, a student intern in the
laboratory of Dr. David Derse (reprinted with permission of the Frederick News-Post and Randall Family, LLC as published on May 16, 2007):

She speaks four languages, interns at NCI- and she's only 18

Press Releases and Related Articles on Bevirimat (PA-457), a Novel HIV-1 Inhibitor

The following articles announce the results of clinical trials on bevirimat (PA-157), the first-in-class HIV-1 maturation inhibitor developed by Panacos Pharmaceuticals
in collaboration with a research team in the HIV Drug Resistance Program, National Cancer Institute (to view the articles, click
on the titles below):

May 2007 Press Release from Panacos Pharmaceuticals:
Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos' Bevirimat

August 2006 Article in the Boston Globe:
Chinese Herb May Yield Drug for AIDS

June 2006 Press Release from Panacos Pharmaceuticals:
Panacos Presents Data on Lack of Clinical Resistance Development to Bevirimat (PA-457) at International
HIV Drug Resistance Conference

June 2006 Article in Scientific American:
A New Assault on HIV: The Constant
Search for Weak Points in the Virus Yields Ideas for a Wholly New Class of Drug

April 2006 Press Release from Panacos Pharmaceuticals:
PA-457 Phase 2b Trial Design Agreed with FDA; Study Projected to Begin in Q2 2006

August 2005 Press Release from Panacos Pharmaceuticals:
Panacos Drug Candidate PA-457 Shows Potent Antiviral Activity in HIV-infected Patients; Viral Load Reduction Meets Primary Endpoint of Phase 2a Study

May 2005 Press Release from Panacos Pharmaceuticals:
V. I. Technologies and Collaborators Present Three Studies on the Molecular Target of PA-457, First-in-Class HIV Maturation Inhibitor, at the Cold Spring Harbor Retrovirus Conference

BusinessWeek online:
A Better Way To Ambush AIDS?�Panacos Pharmaceuticals' experimental drug opens the door to a new line of attack

To view the published results of a study elucidating the mechanism of action of PA-457, go to Proc.
Natl. Acad. Sci. USA 100: 13555-13560, 2003.

Popular Mechanics Feature and Related Articles on the RT-SHIV Animal Model of HIV Infection

The following articles describe research performed by Drs. Vineet
KewalRamani and Zandrea Ambrose on the RT-SHIV animal model of HIV-1 pathogenesis, persistence, and response to
antiretroviral therapy (to view the articles, click on the titles below):

December 2006 PopularMechanics.com World AIDS Day special on the RT-SHIV research in Dr. KewalRamani's lab:
Fighting HIV by Building a New Killer

The original article by Ambrose et al. describing the RT-SHIV model (J. Virol. 78: 13553-13561, 2004):
In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse
transcriptase to study antiviral resistance in pigtail macaques

9th Annual Symposium on Antiviral Drug Resistance: Targets and Mechanisms
The 9th Annual Symposium on Antiviral Drug Resistance: Targets and Mechanisms will be held November 16-19, 2008, at the Virginia Crossings Resort in Richmond, Virginia. Sponsored by the University of Pittsburgh and co-sponsored by the HIV Drug Resistance Program, NCI, this annual meeting brings together researchers in a variety of virus systems to exchange new information on viral targets for therapy, on antiviral drugs, and on resistance to these drugs. The focus is on specific molecular targets, their normal structure and function, their interactions with antiviral drugs, and the evolutionary basis and specific mechanisms of viral resistance. Organized by molecular target, the program includes invited speakers as well as oral and poster presentations selected from submitted abstracts. Invited speakers who have confirmed their participation in this year's Symposium include Paul Ahlquist, Paul Bieniasz, Juan Bonifacino, Michael Emerman, Alan Frankel, Graham Hatfull, Theodora Hatziioannou, James Hurley, John Johnson, Max Nibert, Rolf Renne, Michael Rossmann, Olivier Schwartz, Derek Smith, and Kanta Subbarao. Further details, including information about online registration and abstract submission, are available at the Symposium website

This page was last updated on 7/30/2008.